Search results
PROMOTED
Stay up to date with the latest clinical evidence in transthyretin amyloid cardiomyopathy (ATTR-CM) with this video series spotlighting key cardiomyopathy updates presented at ESC Heart Failure Congress (HFA) 2026.In the first session, Dr Mathew Maurer (Columbia University, New York, US) takes a deep dive into the CARDIO-TTRansform data, exploring the current treatment landscape and ongoing unmet…
View more
Spotlight on HFA 2026: Updates on Cardiomyopathies
Added:
3 weeks ago
Video Series
ARNI for Optimising HFrEF Management
Added:
10 months ago
Expert Opinion
Reverse Remodelling in HFrEF
Added:
6 months ago
Review Article
Added:
8 months ago
Source:
Radcliffe Cardiology
AUTHOR: Yazmin SadikNew findings from the DIGIT-HF trial indicate that adding low-dose digitoxin to guideline-directed medical therapy (GDMT) can reduce the risk of hospitalisation and all-cause mortality in patients with symptomatic heart failure with reduced ejection fraction (HFrEF).¹The results were presented at the European Society of Cardiology (ESC) Congress 2025 and simultaneously…
View more
Added:
3 weeks ago
HFA Congress 2026 — Dr Lars Lund (Karolinska Institute and Karolinska University Hospital, Stockholm, SE) joins us to discuss findings from GOAL-HF1, a randomised, double-blind, placebo-controlled phase 1b/2a trial evaluating AC01 in patients with heart failure with reduced ejection fraction (HFrEF).This first-in-patient study assessed the safety, tolerability and exploratory efficacy of AC01 — a…
View more
Added:
1 year ago
ESC HF 25 - Safety outcomes from PRAISE-HFrEF show that glucagon-like peptide-1 receptor agonism (GLP-1 RA) treatment for heart failure with reduced ejection fraction (HFrEF) and obesity was not associated with increased risk of heart failure hospitalisation or mortality compared to placebo, with greater benefits observed in patients with higher BMI.Dr Varun Sundaram (Case Western Reserve…
View more
Added:
9 months ago
ESC Congress 2025 - Digitoxin reduced the risk of all-cause mortality and hospitalisation in patients with worsening heart failure.Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Udo Bavendiek to explore the DIGIT-HF trial, investigating whether digitoxin can improve outcomes in patients with advanced chronic heart failure and reduced ejection fraction.This landmark study…
View more
Added:
2 weeks ago
Pharmacological Therapy of HFrEF in 2025
Added:
10 months ago
Review Article
Benefits of Spironolactone: Win Ratio Analysis of the TOPCAT Trial
Added:
7 months ago
Original Research